0059 GMT - The steep fall in Monash IVF's share price following another incident at one of its laboratories has raised the chances of it becoming a takeover target, reckons Ord Minnett. Monash IVF's share price fell by around 1/4 after it disclosed a new incident at its Clayton laboratory in southeastern Australia. That extended a stock decline that happened after an earlier incident in Brisbane. Monash IVF's CEO has since resigned. Analyst Tom Godfrey says these developments have heightened risks including weaker new patient volumes, potential doctor losses and increased regulation. "With Monash IVF now trading at 6.7x adjusted Ebitda (versus competitors at >12x) we see increased risk of Private equity/strategic interest," Ord Minnett says. Monash IVF is up 1.5% at A$0.67. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
June 12, 2025 20:59 ET (00:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.